Business Context and Reporting Period
Company: Teva Pharmaceutical Industries Ltd.
Filing Type: Form 8-K (Current Report)
Date of Report: January 28, 2026
Reporting Period: Full Year and Fourth Quarter ended December 31, 2025
This filing serves as a notification that Teva issued a press release announcing its financial results for the period ended December 31, 2025. The detailed results are contained in Exhibit 99.1 and are incorporated by reference.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data. Consequently, the following metrics are not available in this document:
- Revenue: Not provided in filing text.
- Profit: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. Investors must refer to the press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the issuance of a press release regarding 2025 full-year and fourth-quarter results but does not include the text of the commentary, guidance, or outlook.
Risks and Contingencies: No specific risks or contingencies are detailed in this cover document.
Unusual Items: No unusual items are described in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 ("Teva Reports 2025 Full Year and Fourth Quarter Financial Results") for actual revenue, earnings, and cash flow figures.
- Verify the specific details of the fourth-quarter performance and full-year 2025 guidance within the referenced press release.
- Confirm any updates to forward-looking statements or risk factors that may have been disclosed in the press release but not summarized in this 8-K cover page.